Systems and methods for determining lesion depth using fluorescence imaging
Through NADH fluorescence imaging technology, the depth of cardiac injury foci is monitored in real time, which solves the recurrence problem caused by the middle gap of atrial fibrillation ablation, improves the ablation effect and durability, and reduces the treatment cost and recurrence rate.
Patent Information
- Application Number
- CN202010834384.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2013-11-14
- Filing Date
- 2014-11-14
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2034-11-14
AI Technical Summary
The recurrence rate of existing atrial fibrillation ablation methods is as high as 30% to 50% after one year, mainly due to the ineffective ablation caused by the gap in pulmonary vein isolation, the lack of effective deep verification and imaging techniques for lesions of damage, affecting the efficacy and cost of treatment.
Depth of damage foci in cardiac tissues was determined using mitochondrial nicotinamide adenine binucleotide (NADH) fluorescence imaging technology, using UV light to excite NADH fluorescence, combined with 2D and 3D image reconstruction techniques, and real-time monitoring of ablated regions and unablified areas in real time area, providing in-depth information to guide the ablation process.
It improves the success rate and durability of the ablation process, reduces the recurrence rate, reduces the incidence of arrhythmia and treatment costs, and provides high-quality visualization and in-depth information of damage lesions, helping physicians optimize treatment effects.
Smart Images

Figure CN112674861B_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201480062665.3. The original application is the PCT international application PCT / US2014 / 065774 filed on November 14, 2014, which entered the Chinese national phase on May 16, 2016.
[0002] Related Applications
[0003] This application claims the benefit of and priority to U.S. Application Serial No. 14 / 541,991, filed on November 14, 2014, and claims the benefit of and priority to U.S. Provisional Application Serial No. 61 / 904,018, filed on November 14, 2013, the entire contents of both of which are incorporated herein by reference in their entirety. Technical Field
[0004] The present disclosure relates generally to medical procedures that apply ablative energy to the body to form therapeutic lesions. Specifically, the present disclosure relates to systems and methods for imaging lesions and tissue to determine lesion depth. Background Art
[0005] Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the world, currently affecting millions of people. In the United States, AF is expected to affect 10 million people by 2050. AF is associated with increased mortality, morbidity, affects quality of life, and is an independent risk factor for stroke. The substantial lifetime risk of developing AF contributes to the public health burden of the disease, which amounts to more than $7 billion in annual treatment costs in the United States alone.
[0006] It is known that most episodes in patients with AF are triggered by focal electrical activity generated from within the muscle cuffs extending into the pulmonary veins (PV). Atrial fibrillation can also be triggered by focal activity within the superior vena cava or other atrial structures (i.e., other cardiac tissues within the conduction system of the heart). These focal triggers can also cause atrial tachycardia driven by reentrant electrical activity (or rotors), which can then be segmented into multiple electrical wavelets that are characteristic of atrial fibrillation. In addition, long-term AF can cause functional changes in the cardiac cell membranes, and these changes further perpetuate atrial fibrillation.
[0007] Radiofrequency ablation (RFA), laser ablation and cryoablation are the most common techniques based on catheter mapping and ablation systems used by physicians to treat atrial fibrillation. Physicians use catheters to direct energy to destroy focal triggers or form electrical isolation lines that isolate triggers from the rest of the heart's conduction system. The latter technique is often used in so-called pulmonary vein isolation (PVI). However, the success rate of AF ablation methods has remained relatively stagnant, with an estimated recurrence rate of up to 30% to 50% one year after the method. The most common cause of recurrence after catheter ablation is one or more gaps in the PVI line. The gaps are usually the result of ineffective or incomplete ablation, which can temporarily block electrical signals during the method, but will heal over time and promote recurrence of atrial fibrillation.
[0008] Therefore, there is a need to develop and verify appropriate ablations, reduce fluoroscopy time, and decrease arrhythmia rates, thereby improving outcomes and reducing costs. Summary of the invention
[0009] According to some aspects of the present disclosure, a method for determining the depth of an ablation site is provided, the method comprising: irradiating cardiac tissue having a lesion site; obtaining mitochondrial nicotinamide adenine dinucleotide hydrogen (NADH) fluorescence intensity from the irradiated cardiac tissue along a first line spanning the lesion site; creating a two-dimensional (2D) map of the depth of the lesion site along the first line based on the NADH fluorescence intensity; and determining the depth of the lesion site at a selected point along the first line from the 2D map, wherein a lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and a higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0010] In some embodiments, the method further comprises forming a lesion site in the cardiac tissue by ablation. The obtaining step may comprise: detecting NADH fluorescence from the irradiated tissue; creating a digital image of the lesion site from the NADH fluorescence, the digital image comprising a plurality of pixels; and determining the NADH fluorescence intensity of the plurality of pixels along a line across the lesion site. In some embodiments, the method further comprises: distinguishing the lesion site from the healthy tissue in the digital image based on the amount of the NADH fluorescence from the lesion site and the healthy tissue; and normalizing the digital image based on the NADH fluorescence intensity of the pixels representing the healthy tissue.
[0011] In some embodiments, the detecting step comprises filtering the NADH fluorescence through a bandpass filter of about 435 nm to 485 nm. In some embodiments, the healthy tissue has a brighter appearance and the lesion has a darker appearance. The creating step may comprise plotting the NADH fluorescence intensity along the line across the lesion to create a 2D map of the depth of the lesion.
[0012] In some embodiments, the method further comprises: obtaining NADH fluorescence intensity from the irradiated cardiac tissue along a second line across the lesion; creating a 2D map of the depth of the lesion along the second line based on the NADH fluorescence intensity; and constructing a 3-dimensional (3D) image of the lesion from the 2D map along the first line and the 2D map along the second line. In some embodiments, the obtaining, creating, and determining steps may be repeated multiple times along a vertical line across the width of the lesion, each 2D map of the depth being parallel to the first line along the length of the lesion; and integrating each of the 2D maps of the depth of the lesion on the vertical lines to reconstruct a 3D image of the depth of the lesion.
[0013] The determining step may include applying a pixel grayscale ranging from completely black to completely white.The method may be used to analyze epicardial tissue, endocardial tissue, atrial tissue, and ventricular tissue.
[0014] In some embodiments, the irradiating step includes irradiating the cardiac tissue with UV light generated by a laser, wherein the UV light generated by the laser may have a wavelength of about 300 nm to about 400 nm.
[0015] According to some aspects of the present disclosure, a system for imaging cardiac tissue is provided, the system comprising: an irradiation device configured to irradiate tissue having a lesion site to excite nicotinamide adenine dinucleotide hydrogen (NADH) of mitochondria in the tissue; an imaging device configured to detect NADH fluorescence from the irradiated tissue; and a controller in communication with the imaging device, the controller being programmed to obtain NADH fluorescence intensity from the irradiated tissue along a first line spanning the lesion site; create a 2-dimensional (2D) map of the depth of the lesion site along the first line based on the NADH fluorescence intensity; and determine the depth of the lesion site at a selected point along the first line from the 2D map, wherein a lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and a higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0016] According to some aspects of the present disclosure, a system for imaging cardiac tissue is provided, comprising: a catheter having a distal region and a proximal region; a light source; an optical fiber extending from the light source to the distal region of the catheter to irradiate tissue having a lesion site near the distal end of the catheter to stimulate nicotinamide adenine dinucleotide hydrogen (NADH) in mitochondria in the tissue; and an image beam. A digital image processing apparatus is provided for detecting NADH fluorescence from irradiated tissue; a camera connected to the image bundle, the camera being configured to receive the NADH fluorescence from the irradiated tissue and generate a digital image of the irradiated tissue, the digital image comprising a plurality of pixels; and a controller communicating with the camera, the controller being configured to determine, from the digital image, NADH fluorescence intensities of the plurality of pixels along a first row spanning the lesion site; create a 2D map of the depth of the lesion site along the first row based on the NADH fluorescence intensities; and determine, from the 2D map, the depth of the lesion site at a selected point along the first row, wherein lower NADH fluorescence intensities correspond to greater depths in the lesion site and higher NADH fluorescence intensities correspond to non-ablated tissue. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] The presently disclosed embodiments will be further explained with reference to the accompanying drawings, in which like structures are represented by like numerals throughout the several views. The drawings shown are not necessarily drawn to scale, with emphasis instead generally being placed upon illustrating the principles of the presently disclosed embodiments.
[0018] Figure 1A It is a system structure diagram of an implementation scheme system of the present disclosure.
[0019] Figure 1B is a block diagram of an implementation system of the present disclosure.
[0020] Figure 1C is a diagram illustrating an exemplary computer system suitable for use with the systems and methods of the present disclosure.
[0021] Figure 2 is a diagram of a specialized catheter according to one embodiment of the present disclosure.
[0022] Figure 3 is a close-up photograph of an inflated catheter balloon and tip according to one aspect of the present disclosure.
[0023] Figure 4A is a flow chart of a method according to the present disclosure.
[0024] Figure 4B is a flow chart of a method according to the present disclosure.
[0025] FIG. 4C to FIG. 4F Depth analysis along a single row is shown in accordance with the present disclosure.
[0026] Figure 4G and Figure 4H A depth analysis in 3D according to the present disclosure is shown, wherein two ablation lesions and the inter-lesion gap are imaged by fNADH.
[0027] Figure 5A and Figure 5B Is healthy heart tissue ( Figure 5A ) and ablated cardiac tissue ( Figure 5B )'s emission wavelengths;
[0028] Fig. 6A and Figure 6B is the cardiac damage lesion under white light irradiation ( Fig. 6A ) and NADH fluorescence due to UV light irradiation ( Figure 6B ) side-by-side image comparison.
[0029] Fig. 7A are photographs showing epicardial images viewed under UV illumination showing lesion diameter measurements.
[0030] Figure 7B yes Fig. 7A Photographs of the same lesion measured in diameter but stained with triphenyltetrazolium chloride (TTC).
[0031] Figure 7C is a graph of the correlation of lesion size diameter measurements for fluorescent lesions and TTC-stained lesions.
[0032] Fig. 8A It is a graph showing the correlation between the lesion depth and NADH fluorescence.
[0033] Figure 8B These are photographs showing the diameter measurements of two lesions revealed by staining with TTC.
[0034] Figure 8C These are photographs showing the diameter measurements of lesion lesions visualized by fNAHD.
[0035] Fig.8D yes Figure 8C The inverted signal.
[0036] Fig. 9 is a graph of compiled data comparing lesion depth to trans-NADH fluorescence intensity.
[0037] Fig.10 is a 3D reconstruction of the lesion depth.
[0038] Fig.11 is a graph of NADH fluorescence intensity versus lesion depth as a function of ablation duration (time).
[0039] Fig. 12A and Fig. 12B Examples of lesions formed by cryoablation and 3D images of lesions are respectively illustrated.
[0040] Fig. 12C and Fig.12D Examples of lesions formed by radiofrequency ablation and 3D images of the lesions are respectively illustrated.
[0041] Fig.12E and Fig.12F Three different lesions are illustrated respectively and a 3D map showing the physical relationship of the corresponding depths of the lesions is illustrated. Interlesion spacing is illustrated on the 3-D reconstructed image.
[0042] Fig.13A This is an image of a lesion formed by a cryoprobe.
[0043] Fig. 13B yes Fig.13A Amplification of the lesion.
[0044] Fig. 13C is through Fig.13A 3D image of the lesion formed by the cryoprobe.
[0045] Fig.14 Graph showing epicardial fNADH intensity that correlates inversely to actual lesion depth measured by TTC analysis.
[0046] Although the above-mentioned drawings illustrate the presently disclosed embodiments, as noted in the discussion, other embodiments may also be considered. The present disclosure presents illustrative embodiments by way of representation and not limitation. Those skilled in the art may devise many other modifications and embodiments that fall within the scope and spirit of the principles of the presently disclosed embodiments. DETAILED DESCRIPTION
[0047] The present disclosure generally relates to medical procedures in which radiofrequency, laser or cryoablation energy is applied to the body to form therapeutic lesions. Specifically, the present disclosure relates to systems and methods that can use mitochondrial nicotinamide adenine dinucleotide hydrogen (NADH) fluorescence (fNADH) to image cardiac lesions and tissues. The present system and method can be used in the treatment of atrial fibrillation (AF). Specifically, the present disclosure relates to systems and methods for generating a lesion depth map by analyzing NADH fluorescence intensity data to determine the depth of the lesion. In some embodiments, the present system and method can be used to determine the depth of the lesion in cardiac tissue (epicardial tissue, endocardial tissue, atrial tissue and ventricular tissue). However, the currently disclosed methods and systems can also be applied to analyze lesions in other tissue types. Lesions to be analyzed can be generated by ablation during an ablation process. In some embodiments, the methods and systems disclosed herein can also be used to analyze existing lesions generated by ablation or by other means.
[0048] According to some aspects of the present disclosure, endogenous NADH fluorescence (fNADH) in cardiac tissue can be imaged in real time to identify ablated and non-ablated areas. fNADH imaging can be used to identify gaps between ablated areas, and the gaps can then be ablated. Imaging can be performed during ablation and does not require additional chemicals, such as contrast agents, tracers, or dyes.
[0049] In some embodiments, the intensity of fluorescence can be measured and the fluorescence intensity can be plotted, where the lowest fluorescence (darkest) corresponds to the deepest ablated lesion, and the highest fluorescence (brightest) corresponds to unablated or healthy tissue. Any grayscale level between the bright and dark ends generally corresponds to the degree of depth of the tissue lesion. The currently disclosed system and method can be used to determine the depth of the lesion based on the pixel intensity obtained after the tissue is ablated and the tissue is imaged using the fNADH system. In some embodiments, the relevant depth data can be integrated into a 3D reconstruction of the lesion that provides timely feedback to the physician on the geometry and quality of the lesion. Therefore, the present disclosure solves the problem of lack of lesion quality feedback in the known techniques and methods today by providing lesion depth information to the physician when performing the process. For example, having depth information can be used for subsequent diagnosis and treatment. In performing an ablation process (specifically a pulmonary vein isolation process), at least one of the multiple purposes is to deliver an ablation lesion that is deep enough to have a lasting result and improve the success rate of the operation. In this process, it is best that the ablation lesion has no gaps and each lesion has covered a sufficient depth. This is called a transmural lesion (which means that the tissue outside the heart is not damaged or perforated), so that the depth information is used during the process to help the operator make better lesions that are deep enough to provide appropriate results and more lasting results. In addition, the lesions produced depend largely on the ablation tools used, such as RFA (standard or perfusion), cryotherapy (catheter or balloon), and lasers, all of which produce lesions of different shapes. It is a challenge to overcome the dependence of the lesions produced on the ablation tools used, which makes each ablation tool result in different depths, some of which are deeper than other depths. In the process of performing an ablation, there is no minimum depth number, which can depend on several factors, such as the area being ablated, the atrium is thinner than the ventricle, or some other factors. For example, a depth of 2mm may be optimal for atrial tissue, but may be poor for ventricular tissue, however, each patient will have tissue of different thicknesses and require specific attention.
[0050] As mentioned above, high-quality and verifiable lesions can be at least some of the key factors in the success of the ablation procedure and the avoidance of recurrence. A quality lesion can have sufficient depth and cause complete necrosis of cells from the endocardial surface to the epicardial surface of the heart (i.e., transmural), while minimizing damage to external non-cardiac structures. However, the currently disclosed mapping system and other aspects of the system and method provide feedback on the extent of cellular damage caused by ablation and on the integrity of the lesion to be verified. Therefore, by providing the physician with lesion visualization and lesion depth information while performing the procedure, the currently disclosed embodiments particularly address the problem of the lack of lesion quality feedback in today's known technologies.
[0051] See also Figure 1A and Figure 1B , the ablation visualization system (AVS) of the present disclosure may include: a light source 130A (such as a UV laser) outside the patient's body, and an optical device or light delivery fiber 130B for delivering light from the light source into the patient's body; a camera 135A with appropriate filtering (if necessary) and an image beam 135B connected to the camera; and a computer system 140 with one or more displays 140A (for technicians) and 140B (for physicians) having image processing software on its processor or controller.
[0052] As an example, Figure 1C 2 is a diagram showing a typical processing structure that can be used in conjunction with the methods and systems of the present disclosure. Computer processing device 200 can be coupled to display 212 for graphical output. Processor 202 can be a computer processor 204 capable of executing software. A typical example can be a computer processor (e.g., or Processor 204 may be coupled to memory 206, which may be a volatile RAM memory for storing instructions and data while processor 204 executes. Processor 204 may also be coupled to storage device 208, which may be a non-volatile storage medium, such as a hard drive, a flash drive, a tape drive, a DVDROM, or a similar device. Although not shown, computer processing device 200 typically includes various forms of input and output. I / O may include a network adapter, a USB adapter, a Bluetooth radio, a mouse, a keyboard, a touchpad, a display, a touch screen, an LED, a vibration device, a speaker, a microphone, a sensor, or any other input or output device for use with computer processing device 200. Processor 204 may also be coupled to other types of computer-readable media, including but not limited to electronic, optical, magnetic, or other storage or transmission devices that can provide computer-readable instructions to a processor such as processor 204. Various other forms of computer-readable media can transmit instructions to a computer or carry instructions to a computer, including routers, private or public networks, or other transmission devices or channels that are wired and wireless. The instructions may include code from any computer programming language including, for example, C, C++, C#, Visual Basic, Java, Python, Perl, and JavaScript.
[0053] The program 210 may be a computer program or computer readable code containing instructions and / or data, and may be stored on the storage device 208. The instructions may include code from any computer programming language, including, for example, C, C++, C#, Visual Basic, Java, Python, Perl, and JavaScript. Typically, the processor 204 may load some or all of the instructions and / or data of the program 210 into the memory 206 for execution. The program 210 may be any computer program or process, including, but not limited to, a web browser 166, a browser application 164, an address registration process 156, an application 142, or any other computer application or process. The program 210 may include a variety of instructions and subroutines, which, when loaded into the memory 206 and executed by the processor 204, cause the processor 204 to perform a variety of operations, some or all of which may implement the method for managing medical care disclosed herein. The program 210 may be stored on any type of non-transitory computer-readable medium, such as, but not limited to, a hard drive, a removable drive, a CD, a DVD, or any other type of computer-readable medium.
[0054] It is possible that the light source 130A may include a cart 132. In some embodiments, the system may also include a dedicated catheter 105A, which includes an inflatable balloon 105B. In some embodiments, the image bundle 135B and the light delivery fiber may extend from the outside of the catheter to the distal region of the catheter inside the balloon 105B. It is conceivable that there may be multiple components added to each part of the system disclosed above. The system may also include a guidewire 105C for the catheter, an EP fluorescent system 160, a sterable sheath 165A, a guidewire 165B for the sterable sheath, an introducer sheath kit 165C, an indeflator 170, and a transseptal kit 180.
[0055] Figure 1B is a block diagram of an exemplary system according to the present disclosure. The AVS system includes an external instrument 125 having a light source 130A, a camera 135A with appropriate filtering as needed, and a computer system (not shown) having one or more displays 140A and image processing software. The AVS system includes an internal instrument including an ablation device 140, an irradiation device 130B, and an imaging device 135B, wherein the internal components are within an internal balloon 105B associated with a catheter 105A. It should be noted that the internal instrument including the catheter 105A and the inflatable balloon catheter 105B is coupled to the external instrument 125. In some embodiments, the irradiation device 130B and the imaging device 135B can utilize fiber optic waveguides to transmit light to and from the treatment tissue.
[0056] Still refer to Figure 1A and Figure 1B , light source 130A may include a laser as an illumination source for the myocardium. The output wavelength of the laser may be within the absorption range of the target fluorophore (in this case, NADH) so as to induce fluorescence in healthy myocardial cells. In some embodiments, the laser may be a UV laser.
[0057] according to Figure 1A and Figure 1BIn some aspects of the invention, laser-generated UV light can provide more irradiation power, and its wavelength can be purified at any number of nanometers that may be needed. Emissions of more than one wavelength may be problematic, in that they may cause other molecules to fluoresce (rather than NADH), and they may cause reflections in the reflection range to inject image noise or worse, thereby overwhelming the NADH reflection signal. There are commercial lasers that can emit the desired irradiation band, and they can be used at many power settings close to 50 to 200 mW or higher. In some embodiments, an instant system uses a laser with adjustable power up to 150 mW.
[0058] The wavelength range on the illumination source can be defined by the anatomical structure of interest, particularly selecting a wavelength that results in maximum NADH fluorescence rather than too much collagen fluorescence that is only activated by slightly longer wavelengths. In some embodiments, the laser has a wavelength of 300nm to 400nm. In some embodiments, the laser has a wavelength of 330nm to 370nm. In some embodiments, the laser has a wavelength of 330nm to 355nm. In some embodiments, 355nm can be used because it is adjacent to the peak of NADH excitation and is just less than collagen excitation. The output power of the laser can be high enough to produce recoverable fluorescence data, but not so high as to cause cell damage.
[0059] Still refer to Figure 1A and Figure 1B , catheter 105A may be employed to perform a number of functions including, but not limited to, vascular navigation, blood replacement, propagation of light from light source 130A to the myocardium, and image acquisition of fluorescence. An example of a suitable catheter is disclosed in co-owned U.S. Application No. 13 / 624,902, the entire contents of which are incorporated herein. In some embodiments, ablation techniques are housed or integrated within system and catheter embodiments.
[0060] Reference Figure 2 and Figure 3, the catheter 105A may include a balloon 105B at or near the distal end of the catheter 105A. Since blood absorbs irradiation and fluorescence wavelengths, the balloon 105B can displace blood from the myocardial surface. To do so, the balloon 105B can be inflatable and compliant to be well positioned within the anatomical structure, particularly the pulmonary vein. The medium used to inflate the balloon 105B can also be optically transparent, but is ideally fluorescent opaque for navigation purposes. Suitable inflation media include, but are not limited to, deuterium (heavy water) and CO2, which meet these two requirements. The balloon 105B can also be made of a material that is optically transparent at least at the wavelength of the myocardial irradiation and fluorescence of interest. The balloon 105B can be made of a non-compliant material with an optimally variable size that best fits the pulmonary vein and other structures, or made of a compliant material such as silicone or urethane. In some embodiments, the balloon 105B can be optically transparent in the UV range of 330nm to 370nm.
[0061] In some embodiments, balloon 105B is optically transparent from 330 nm to 370 nm for UV irradiation and from 400 nm to 500 nm for fluorescent wavelengths. Suitable UV transparent materials for the balloon include, but are not limited to, silicone and urethane.
[0062] Still refer to Figure 2 and Figure 3 , catheter 105A can also be used to efficiently deliver illumination light (e.g., UV laser and optionally white light) from an external light source to balloon 105B and out of balloon 105B to the myocardium. In some embodiments, laser delivery fibers, which are typically made of quartz due to its UV efficiency and small diameter, can be used to deliver illumination light from a UV laser light source.
[0063] You can also use Figure 2 and Figure 3 The catheter collects and transmits the light of NADH fluorescence from the irradiated tissue to an external camera (refer to Figure 1A and Figure 1B In some embodiments, this can be done via an imaging fiber bundle extending from the distal region of the catheter to an external camera (see Figure 1A ) to achieve this. In some embodiments, the imaging bundle can include one or more of the individual single mode optical fibers that together maintain image integrity while transmitting the image along the length of the catheter to the camera and filters as needed. Despite being flexible and small in diameter, the imaging bundle can achieve a sufficient field of view to image the target tissue area covered by the balloon.
[0064] The camera can be connected to a computer system (see Figure 1A) for viewing, and can have high quantum efficiency at wavelengths corresponding to NADH fluorescence. One such camera is the Andor iXon DV860. A light bandpass filter of 435nm to 485nm (460nm in some embodiments) can be inserted between the imaging beam and the camera to block light outside the NADH fluorescence emission segment. In some embodiments, other light bandpass filters can be inserted between the imaging beam and the camera to block light outside the NADH fluorescence emission segment selected based on the peak fluorescence of the tissue being imaged.
[0065] In some embodiments, the digital image produced by the camera is used to perform 2D and 3D reconstruction. In some embodiments, the image beam can be connected to a camera, which can generate a digital image that can be displayed on a computer from NADH fluorescence (fNADH). The computer processor / controller has data on the pixel intensity of the pixels used to form the digital image, so the computer processor / controller can use a 2D or 3D program to generate a depth correlation map. In some embodiments, NADH fluorescence can be transmitted directly to the computer processor / controller.
[0066] Reference Figure 4A , illustrating the operation of the system of the present disclosure. Initially, (step 410) a catheter is inserted into an area of cardiac tissue affected by atrial fibrillation, such as the pulmonary vein / left atrium junction or another area of the heart. For example, blood is moved out of the field of view by a balloon. For atrial fibrillation ablation, a transparent balloon around a fiber optic waveguide can be used to displace the blood at the pulmonary vein / left atrium junction. The affected area can be irradiated by ultraviolet light from a light source and an optical fiber or another irradiation device (step 415). Before or after irradiation, an ablation device can be used to ablate tissue in the irradiated area (step 420). Using the system of the present disclosure, point-to-point RF ablation or cryo or laser or other known ablation procedures can be used. Ablation is performed by passing the tip across the central lumen of the catheter or the outside of the catheter. After the process, the ablation tip can be withdrawn. In some embodiments, the ablation tip can be incorporated into the catheter disclosed herein.
[0067] Still refer to Figure 4A, the irradiated area is imaged by a combination of an imaging beam and a camera (step 425). In some embodiments, the methods of the present disclosure rely on fluorescence emission imaging of NADH, which is the reduced form of nicotinamide adenine dinucleotide (NAD+). NAD+ is a coenzyme that plays an important role in the aerobic metabolic redox reactions of all living cells. It acts as an oxidant by accepting electrons from the citric acid cycle (tricarboxylic acid cycle), which occurs in the mitochondria. Through this process, NAD+ is therefore reduced to NADH. NADH and NAD+ are most abundant in the mitochondria, the respiratory unit of the cell, but are also present in the cytoplasm. NADH is an electron and proton donor in the mitochondria to regulate the metabolism of the cell and is involved in many biological processes, including DNA repair and transcription.
[0068] By measuring the UV-induced fluorescence of tissues, the biochemical state of the tissues can be understood. NADH fluorescence has been studied for its use in monitoring the metabolic activity of cells and cell death. Several studies in vitro and in vivo have investigated the potential of using the fluorescence intensity of NADH as an intrinsic biomarker for monitoring cell death (apoptosis or necrosis). When NADH is released from the mitochondria of damaged cells or converted into its oxidized form (NAD+), its fluorescence decreases significantly, making it very useful for distinguishing healthy tissue from damaged tissue. During ischemic conditions when oxygen is not available, NADH can accumulate in cells, thereby increasing the fluorescence intensity. However, in the case of dead cells, NADH disappears altogether. The following table summarizes the different states of relative intensity due to NADH fluorescence:
[0069]
[0070]
[0071] Still refer to Figure 4A , although both NAD+ and NADH absorb UV light quite readily, NADH is autofluorescent in response to UV excitation and NAD+ is not. NADH has a UV excitation peak of about 350nm to 360nm and an emission peak of about 460nm. In some embodiments, the methods of the present disclosure may use an excitation wavelength of about 330nm to about 370nm. Therefore, with appropriate instrumentation, the emission wavelength can be imaged while measuring hypoxia and necrotic tissue in the target area in real time. In addition, the grayscale rendering ratio of NADH fluorescence can be used to achieve relative measurement.
[0072] Under hypoxic conditions, oxygen levels drop. The intensity of the fNADH emission signal can then increase, indicating an excess of mitochondrial NADH. If hypoxia is not detected, full attenuation of the signal will eventually occur as the affected cells die along with their mitochondria. The high contrast of NADH levels can be used to identify the periphery of terminally damaged ablated tissue.
[0073] Still refer to Figure 4A To initiate fluorescence imaging, the operator can deploy a balloon mounted on the distal portion of the catheter. Next, NADH is excited by UV light from a light source, such as a UV laser. NADH in the tissue specimen absorbs light of the excitation wavelength and emits light of a longer wavelength. The emitted light can be collected and transmitted back to the camera, and a display of the imaged irradiated area can be generated on a display (step 430), which is used to identify ablated and non-ablated tissue in the imaging area using NADH fluorescence (step 435). Then, if additional tissue needs to be ablated, the process can be repeated by returning to the ablation step. It should be recognized that although Figure 4A The steps are illustrated as being performed sequentially; however, many of these steps can be performed simultaneously or nearly simultaneously, or in a manner similar to that of Figure 4A For example, ablation, imaging, and display can occur simultaneously, and identification of ablated and non-ablated tissue can occur while ablation of tissue is taking place.
[0074] Application software executed by a processor or computer on a computer system can provide an interface with the physician to the user. Some of the main functions may include: laser control, camera control, image capture, image adjustment (brightness and contrast adjustment, etc.), lesion identification, lesion depth analysis, procedure event logging, and file operations (create, edit, delete, etc.).
[0075] Figure 4B A flow chart illustrating the process of determining lesion depth is shown. Step 440 discloses using NADH fluorescence from a computer display via application software to identify ablated and non-ablated tissue in an imaged area. Step 445 discloses identifying a lesion-specific image of interest to begin lesion depth analysis. Step 450 discloses identifying healthy tissue regions within the image of the lesion of interest. By way of a non-limiting example, reference is made to Fig. 6A and Figure 6B , imaging fluorescence of NADH in the heart can produce: physiological displays of lesion sites with a dark appearance due to lack of fluorescence; physiological displays of gaps with a bright appearance due to normal fluorescence; and physiological displays of any ischemic tissue with a brighter halo-like appearance near the lesion site (see Fig. 6A and Figure 6B). When lesions were identified, they were selected for lesion depth analysis.
[0076] Step 455 discloses normalizing the entire image using the ratio of the NADH fluorescence intensity observed at each pixel to the NADH fluorescence intensity observed in the identified healthy tissue. Step 460 discloses processing the resulting normalized image data via an algorithm derived from a pre-established data set that correlates the normalized intensity ratio with the lesion depth. The lesion depth can be calculated using the ratio of the fluorescence of the healthy tissue to the fluorescence of the lesion tissue. First, the user identifies an area of healthy tissue within the image. Then, the application software normalizes the entire image using the ratio of the NADH fluorescence intensity observed at each pixel to the NADH fluorescence intensity observed in the identified healthy tissue. Then, the resulting normalized image data is processed via an algorithm derived from a pre-established data set that correlates the normalized intensity ratio with the lesion depth. By using the patient's own myocardial NADH fluorescence as a control, this method greatly reduces the impact of absolute NADH fluorescence variations between patients, as well as losses in the illumination light and imaging system and variations in light intensity due to specular and diffuse reflections, and other optical non-ideal properties.
[0077] Step 465 discloses performing a depth analysis along a single row across the lesion. It is also possible to perform a depth analysis for a single location in the lesion from information from a single location, row or region. Figures 4C to 4F A depth analysis along a single line is shown. For example, Figure 4C Shown is an image of a canine heart that has been ablated six times. The square encloses a single ablation lesion. Figure 4D Shown in the upper right corner is a NADH fluorescence (fNADH) image obtained from the same region of a blood-perfused canine heart. Figure 4E is carried out in a single line and is based on Figure 4D A 2D depth map generated from a digital image in (i.e., from the pixel intensities that form the digital image). Figure 4F is a hematoxylin and eosin-stained canine heart tissue cut along the same line, which shows the actual depth of the lesion (the square shows the boundary of the lesion), where the deepest area corresponds to Figure 4D The darkest spots and Figure 4E The lowest fNADH in
[0078] Step 470 discloses repeating steps 460 to 470 along different lines parallel to the initial line, so that the depth data of each line is compiled into a 3D reconstruction model of the lesion site. The depth analysis process performed along a single line across the lesion can be repeated multiple times along lines different from the initial line as needed, and the depth data of each line can be compiled into a 3D reconstruction model of the lesion site.
[0079] By way of non-limiting example, Figure 4G Digital images of two ablation lesions and the gap between the lesions imaged by fNADH are shown. Figure 4H Shown by Figure 4G 3D reconstruction of pixel intensities in a digital image. As mentioned above, both 2D data and 3D data can be used for further diagnosis or treatment.
[0080] The intensity of the fluorescence detected by the camera can be measured and plotted, where the lowest fluorescence (darkest) corresponds to the deepest lesions and the highest fluorescence (brightest) corresponds to unablated or healthy tissue. Any grayscale level between the light and dark extremes generally corresponds to the degree of depth of the tissue lesion. The sensitivity of the camera sensor determines the number of grayscale levels between full black and full white. Several binary numbers are common in such applications, including 256 levels and 65,536 levels corresponding to 8-bit and 16-bit resolutions, respectively. With 8-bit sensitivity, 0 will be full black and 255 will be full white, with 254 grayscale levels in between. Using this grayscale image, an appropriate depth map can be estimated. In some embodiments, 24-bit resolution can also be used.
[0081] It should be noted that fNADH imaging can reliably and reproducibly predict cardiac ablation lesion diameter and depth. The loss of fNADH intensity is related to the actual measured diameter and depth of multiple RF lesions, wherein the correlation coefficients are greater than 96% and 79%, respectively. Since UV irradiation cannot reliably penetrate cardiac tissue below a depth greater than 2 mm, it is possible that correlation loss occurs at a lesion depth greater than 2 mm. With further lesion depth, no further fNADH can be detected, and thus a reproducible platform of fNADH signal intensity is observed at a lesion depth of approximately 2 mm. As measured by CT scans, the average left atrial wall thickness at the location of the left atrium, which is usually targeted for ablation, is 1.85 mm. Therefore, the lowest point and platform of the fNADH signal intensity observed across the RF lesion are used as a reasonable model for clear, all-or-no determination of sufficient lesion depth.
[0082] The methods, systems, and devices disclosed herein can be used for a variety of therapeutic procedures. Exemplary procedures in which the methods, systems, and devices disclosed herein can be used include, but are not limited to: diagnostic and therapeutic procedures in the heart, for treating arrhythmias (such as, for example, supraventricular arrhythmias and ventricular arrhythmias), for treating atrial fibrillation, and pulmonary vein mapping and ablation. The ablated tissue can be myocardium (epicardial or endocardial myocardium), but the methods disclosed herein should have the same effect on skeletal muscle, liver, kidney, and other tissues with significant presence of NADH-rich mitochondria.
[0083] The method disclosed in the present invention can be used with a two-dimensional (2D) to three-dimensional (3D) mapping scheme. Multiple 2D images can be superimposed on a 3D reconstructed image of a tissue or organ (including the heart). Many arrhythmia surgeries include using a reconstructed three-dimensional image of a patient's specific anatomical structure during the surgery. A variety of imaging modalities are used, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and electroanatomical mapping using systems such as NAVX and CARTO. In all cases, a three-dimensional anatomical image or surface presents the patient's specific anatomical structure to help locate the tissue area to be treated. In all cases, being able to visualize the exact location of the formation of lesions and the exact location of the lesion absence (e.g., a "gap" or break in the lesion concentration) will guide surgery to optimize treatment outcomes. Mapping of 2D images to 3D images allows the system to use the patient's specific anatomical structure in a three-dimensional, rotatable, interactive virtual environment to overlay, spatially align, and / or texture map a single or multiple images of tissue (which may indicate the presence or absence of lesions).
[0084] In some embodiments, the system and method of the present disclosure enables the image registration produced by the system and / or is superimposed on the specific anatomical structure of the patient seen using other imaging forms such as MRI images, computed tomography (CT) images, ultrasound images and three-dimensional reconstruction thereof. In some embodiments, the system and method of the present disclosure may also include the image registration produced by the system and / or is superimposed on the specific anatomical structure of the patient seen using other electroanatomical mapping, anatomical reconstruction and navigation systems (such as NAVX and CARTO). Registration and superposition can be performed in real time during the surgical procedure. The NADH image texture is mapped to the endocardial surface of reconstruction to enable visualization of the treatment site. For example, multiple NADH snapshots of lesions can create a complete panoramic image of the entire pulmonary vein opening or multiple pulmonary veins. Placing the sensor on the catheter tip can provide the following information, which enables the NADH image to be combined to create a 3D reconstruction image.
[0085] Provide the embodiment of the system and method using the present disclosure below.These embodiments are merely representative and should not be used to limit the scope of the present disclosure.For the method and device disclosed herein, there are multiple alternative designs.Therefore, the selected embodiment is mainly used to prove the principle of the device and method disclosed herein.
[0086] Example
[0087] Experiments were performed using a functionally equivalent system to generate ablation lesions and lesion images to develop methods for lesion depth analysis. The experimental setup is described below.
[0088] The NADH fluorescence system provides an LED spotlight (PLS-0365-030-07-S, MightexSystems) with a peak wavelength of 365 nm to illuminate the epicardial surface. The emitted light is band-pass filtered at 460 nm + / - 25 nm and imaged using a CCD camera (Andor Ixon DV860) equipped with a low magnification lens. The fluorescence of NADH (fNADH) is imaged to monitor the status of epicardial tissue.
[0089] The RFA system provides the use of a standard clinical RF generator (EPT1000 ablation system of Boston Scientific) to perform RFA. The generator is electrically connected to the animal via a 4mm cooled Blazer ablation catheter (Boston Scientific) to deliver the lesion. A grounding pad is used during ablation. The generator is set to a temperature control mode. Cryoablation is performed using a custom metal probe immersed in liquid nitrogen or by using the Freezor MAX cardiac cryoablation catheter of Medtronic.
[0090] Reference Figure 5A and Figure 5B ,First, baseline data of NADH excitation and emission spectra in healthy heart tissue were obtained. Figure 5A and Figure 5B A tissue excitation-emission matrix is shown. Due to the presence of NADH, healthy tissue emits strongly at 450-470 nm when excited in the range of 330-370 nm. There is no large peak associated with NADH in ablated tissue.
[0091] exist Fig. 6A and Figure 6B An example of a typical RFA lesion is shown in . The image on the left was captured using white light illumination, while the fNADH image on the right was captured using UV excitation with a 460 nm filter.
[0092] All animal protocols were reviewed and approved by the Animal Care and Use Committee of the George Washington University School of Medicine and complied with the guidelines for animal research.
[0093] In vitro experiments were initially performed using excised, bloodless hearts of rats (200-300 g Sprague-Dawly). Animals were heparinized and anesthetized using standard procedures. A midline incision was used to open the chest. The heart was then excised; the aorta was cannulated and ex vivo langendorff perfused at constant pressure. The heart was placed on top of a grounding pad and submerged in 37 degrees Celsius Tyrode's solution during RFA ablation. Alternatively, a cryoprobe was applied directly to the epicardial surface.
[0094] Radiofrequency energy was applied to the epicardium of the excised, bloodless rat ventricle while varying the temperature and duration to produce RFA lesions of varying sizes. A uniform contact force of 2 grams was measured by a calibrated balance. Lesions of varying sizes were generated by varying the temperature (50, 60, and 70 degrees Celsius) and time (10, 20, 30, 40, 50 seconds) of the RF application. A total of 12 RFA lesions were generated on six different rat heart specimens.
[0095] The NADH fluorescence around the lesion and tissue was measured by irradiating the epicardial surface with 365nm UV light using a Mightex Precision LED spotlight. The light corresponding to fNADH was selected using a 460 / 25nm bandpass filter, and a highly sensitive charge-coupled device camera was used for imaging. In addition, the lesion was imaged adjacent to the tape measure with bright light to enable the size of the lesion to be measured. Then, the fNADH image was input into the ImageJ software to measure the size, and the darkness spectrum of each lesion was analyzed. The darkness spectrum was evaluated by measuring the pixel intensity at each point across the periphery of the lesion by placing the linear region of interest (ROI) through the center of the ablation lesion imaged by each fNADH. Then, the ventricular tissue was retrogradely perfused using Tyrode's solution containing triphenyltetrazolium chloride (TTC) to assess tissue necrosis. The epicardial lesion was excised to measure tissue damage with naked eye and histological measurements.
[0096] In the in vivo experiment, a canine open-chest model was used to perform. Animals underwent open-chest surgery after induction of general anesthesia. Using a 4mm radiofrequency ablation catheter, multiple lesions were caused to the epicardial surface with a variety of durations and temperatures. The epicardial surface of the heart was then irradiated with a 365nm UV light (Mightex precisionLED spotlight), and the corresponding fNADH was passed through a 460 / 25nm filter coupled to a high quantum efficiency fluorescent camera (Andor Ixon DV860 camera). The lesion was imaged under bright white light with a tape measure to measure the size of the lesion.
[0097] Provide autopsy after rat experiment, use TTC dyeing animal heart.TTC is the standard procedure for assessing acute necrosis, and this depends on the ability of dehydrogenase and NADH to react with tetrazolium salt to form formazan pigment.The metabolically active tissue appears as crimson and necrotic tissue appears as white.After TTC dyeing, the lesion is divided into two equal parts at the central linear ROI previously defined for pixel intensity analysis, for measuring the lesion depth across the corresponding ROI.Determine and record the lesion morphology, width, length and depth with naked eye inspection.
[0098] For the canine experiments, segments of multiple epicardial lesions were bisected longitudinally and submitted for histological staining (hematoxylin-eosin). The specimens were then analyzed under light microscopy at 40X to characterize morphological changes and to determine the extent of heat-induced cellular damage and necrosis.
[0099] Statistical analysis included lesion size measured by two independent readers performed by fNADH and TTC staining using the means and standard deviations recorded. Correlation coefficients for lesion size obtained by fNADH and by TTC staining were also obtained and recorded.
[0100] Results included epicardial fNADH that correlated first with lesion size. In the rat model, fNADH and triphenyltetrazolium chloride (TTC) staining were delivered and measured in a total of 12 epicardial surface lesions using two independent detectors (see Fig. 7A , Figure 7B and Figure 7C ). Fig. 7A A typical fNADH image is illustrated in Figure 7B Actual lesion diameter measurements using TTC staining are shown in . Linear measurements of lesion diameter using TTC (top image, 7A) correlate with lesion diameter obtained from the corresponding fNADH images (bottom image, 7B). Figure 7C A summary graph of lesion size versus ablation delivery number is shown. For all lesion sizes, epicardial fNADH closely predicted actual lesion diameters determined by TTC staining. NADH and TTC mean diameters were 7.9 ± 1.85 mm and 8.2 ± 1.95 mm, respectively, with a correlation coefficient of 96%.
[0101] Temperature and lesion delivery times were varied to obtain a large number of epicardial surface lesions at varying depths in the rat heart. The intensity of epicardial fNADH was then measured multiple times along the centerline of the lesion. Fig. 8A , Figure 8B , Figure 8C and Fig.8D An example lesion group is shown in Figure 8C The row across lesion #1 in the figure has fNADH plotted on the top graph ( Fig. 8A )middle. Figure 8B Shown are measured depths obtained from TTC-stained hearts spanning the same lesion. Fig.8D As shown in Figure ( Fig. 8A ). This was done so that the higher intensity of the anti-fNADH correlated with the depth of the lesion shown and had a similar shape.
[0102] Reference Fig. 9 and Fig.10 The depth of the lesion was compared with the intensity of the anti-fNADH signal. Fig. 9 In addition, the lesions were delivered at 50 degrees Celsius for 10 seconds, 20 seconds, 30 seconds, 40 seconds and 50 seconds. The same comparison was obtained at varying temperatures and similar findings were shown (see Fig. 9 and Fig.10 ).
[0103] Reference Fig.11 , linear correlation coefficients were obtained for different durations at a specific temperature using the lesions obtained by varying the temperature and lesion duration. Fig.11 Results at 60 degrees Celsius are shown, with correlation coefficients ranging from 0.84 to 0.97, depending on the duration of ablation.
[0104] 3D reconstructions of lesion depth were obtained from canine epicardial images by aggregating the grayscale from each map of fNADH using only 5 parallel rows across the lesion and plotting the values using a 3D plotting program.
[0105] Fig. 12A and Fig. 12B , Fig. 12C and Fig.12D as well as Fig.12E and Fig.12F Higher resolution 3D reconstructions of a cryo-lesion, a radiofrequency lesion, and multiple cryo-lesions are shown, respectively. Note that in the plots showing multiple lesions, variations in lesion depth are visible.
[0106] The experimental results demonstrate that fNADH is an accurate measure of epicardial lesion size and a predictor of lesion depth. A 3D reconstruction of depth can be obtained by repeating the method described above along multiple lines across the ablation image and compiling the results (see Fig.10 , Fig. 12A , Fig. 12B and Fig. 12C ).
[0107] As noted above, Fig.13A shows an fNADH image of an ablation lesion created, for example, using a cryoablation catheter, and Fig. 13B This is an enlarged image of the ablation lesion. Fig. 13C A 3D depth reconstruction of the same ablation lesion is shown in the associated plot. The main difference is that FIG12 includes some ablation lesions created using RFA, where the RFA and cryo lesions have different appearances in 3D.
[0108] Reference Fig.14, RFA lesions can be detected and distinguished from visible tissue with fine resolution because RFA lesions exhibit very low or undetectable fNADH compared to the surrounding healthier myocardial tissue. The lesion diameter imaged by fNADH is closely correlated with the lesion size measured by TTC (mean NADH and TTC diameters were 7.9±1.85 mm and 8.2±1.95 mm, respectively; correlation coefficient [CC] was 96%). The intensity of epicardial fNADH is inversely correlated with the actual lesion depth measured by TTC analysis. Fig.14 As shown, this relationship was reproduced with a CC of more than 79% for all RFA variables up to lesion depth of 1.8 mm (significant p<0.0001), beyond which the fNADH signal intensity saturated and plateaued.
[0109] The relationship between lesion depth and epicardial fNADH was reproduced with statistical significance. Multiple lesions of different sizes were generated on the epicardium of the rat ventricle by varying RF duration and temperature. These multiple lesions were analyzed for lesion depth and anti-fNADH signal intensity. The loss of fNADH intensity was correlated with lesion depth with a Pearson correlation coefficient of 78% and was highly significant (p < 0.0001) up to a lesion depth of approximately 2 mm. Beyond 2 mm, the relationship lost its significance as the fNADH values plateaued.
[0110] In some embodiments, a system for imaging ablated tissue and non-ablated tissue comprises an ultraviolet (UV) laser light source; an inflatable balloon catheter comprising a UV laser guide and an image guide; an external fluorescent camera coupled to the catheter; a computer with a display coupled to the camera; and imaging software.
[0111] In some embodiments, the catheter further comprises a guidewire port for catheter navigation; and / or ablative therapy techniques, including radiofrequency electrodes, laser ablation capability, or cryoablation capability. In some embodiments, the balloon can be made of a compliant material such as silicone or urethane; optionally transparent in the UV range of 330nm to 370nm; or optionally transparent in the fluorescent light range of 430nm to 490nm.
[0112] In some embodiments, a method for estimating lesion depth may include the steps of acquiring and displaying nicotinamide adenine dinucleotide hydrogen (NADH) fluorescence data for tissue; identifying areas of healthy tissue within the image; normalizing the entire image using a ratio of the NADH fluorescence intensity observed at each pixel in the image to the NADH fluorescence intensity observed in the identified healthy tissue; identifying areas of ablated tissue; and applying an algorithm for correlating the resulting normalized image with lesion depth.
[0113] In some embodiments, the correlation algorithm uses the data and then uses a pre-established data set that correlates the normalized intensity ratio with the lesion depth. In some embodiments, the lesion depth estimation uses the patient's own myocardial NADH fluorescence as a control. In some embodiments, ablation is performed by using one or more of the following techniques: radiofrequency ablation, laser ablation, or cryoablation. The tissue can be cardiac tissue. In some embodiments, a cross-sectional drawing of the estimated lesion depth is performed along the line indicated by the user. In some embodiments, a 3D drawing of the estimated lesion depth is performed by compiling a series of cross-sectional views.
[0114] In some embodiments, a method for treating atrial fibrillation is provided, the method comprising: acquiring and displaying NADH fluorescence data in a specific area of cardiac tissue (such as a ostium of a pulmonary vein); analyzing lesion depth across images; identifying healthy cardiac tissue; identifying appropriate lesions; identifying incomplete lesions, if present; identifying ischemic areas (tissue that is injured but not necrotic), if present; reapplying ablation therapy where necessary either to fill identified gaps in lesion rows, or to complete incomplete lesions, or to bridge ischemic areas; repeating the above steps as needed to reacquire and display repaired tissue; and repeating the above steps for other areas of the heart (such as the remaining pulmonary veins, other portions of the left atrium, or even specific areas of the right atrium including the superior vena cava).
[0115] In some embodiments, a catheter having a proximal end and a distal end for imaging ablated epicardial cardiac muscle tissue, non-ablated gaps at the pulmonary vein / left atrial junction, and lesion depth comprises: an inflatable transparent compliant or non-compliant balloon made of a UV transparent material filled with a transparent fluid capable of transmitting light, for displacing surrounding blood to allow visualization of NADH fluorescence at the distal end; an ultraviolet irradiation device for stimulating mitochondrial NADH of pulmonary vein and left atrial tissue using an optical fiber capable of transmitting UV light at the distal end; a microfiberscope for detecting NADH fluorescence from the irradiated pulmonary vein and left atrial tissue at the distal end; and a fluorescence camera located at the proximal end coupled to the microfiberscope for detecting the NADH fluorescence detected by the microfiberscope. The invention provides a method for creating an image of NADH fluorescence by using a fluorescence camera, the fluorescence camera including a 460nm+ / -25nm bandpass filter to detect NADH fluorescence from irradiated pulmonary vein and left atrial tissue captured by a microfiberscope, wherein the detected fluorescence data shows the physiology of a lesion site having a dark appearance due to lack of fluorescence, the physiology of gaps having a bright appearance due to normal fluorescence, and the physiology of any ischemic tissue surrounding the lesion site having a brighter halo-type appearance; and a module for determining the depth of the lesion site along a line by plotting the detected fluorescence intensity along the line spanning the length of the lesion site; wherein the lowest fluorescence intensity measurement corresponds to the deepest point of the lesion site and the highest fluorescence corresponds to non-ablated tissue.
[0116] In some embodiments, the module applies a pixel grayscale ranging from completely black to completely white to create a 2D map of the depth of the lesion site along the row, where 0 is completely black and the darkest point and 255 is completely white and the lightest point assuming 256 (0 to 255) grayscale levels, where the 2D map of the depth of the ablated tissue is an absolute measurement where the fNADH signal intensity is normalized to a previously established fNADH / depth grayscale value.
[0117] In some embodiments, a 2D map of the depth of the ablated tissue is repeated multiple times along vertical lines spanning the width of the lesion site, each 2D map of the depth is parallel to a row along the length of the lesion, and each of the 2D maps of the depth of the ablated tissue on the vertical lines are integrated to reconstruct a 3D image of the depth of the ablated tissue.
[0118] In some embodiments, the catheter also includes a guide wire lumen to insert a flexible guide wire. The camera can be a CCD camera with high quantum efficiency. In some embodiments, the microfiber scope is an optical imaging bundle. In some embodiments, UV irradiation is provided by a laser source of 330nm to 370nm and more specifically 335nm. In some embodiments, the UV irradiation fiber tip is covered with a divergent lens so that the UV light is refracted and dispersed.
[0119] In some embodiments, a method for obtaining real-time images of ablated endocardial cardiac muscle tissue, unablated gaps at the junction of the pulmonary veins and left atrial, and the depth of the lesion includes: an inflatable transparent compliant balloon made of a UV transparent material filled with a transparent fluid capable of transmitting light, for displacing surrounding blood to allow visualization of NADH fluorescence at the distal end; irradiation with ultraviolet light for exciting mitochondrial NADH in the pulmonary veins and left atrial tissue; detection of NADH fluorescence from the irradiated pulmonary veins and left atrial tissue using an optical imaging beam; and visualization of the NADH fluorescence by using a 460 nm bandpass filter. The detected NADH fluorescence is filtered to create an image using a fluorescence camera; wherein the detected fluorescence data shows the physiology of the lesion site having a dark appearance due to lack of fluorescence, the physiology of the gap having a bright appearance due to normal fluorescence, and the physiology of any ischemic tissue surrounding the lesion site having a brighter halo-type appearance; and a module for determining the depth of the lesion site along a row by plotting the detected fluorescence intensity along the row spanning the length of the lesion site; wherein the lowest fluorescence intensity measurement corresponds to the deepest point of the lesion site and the highest fluorescence corresponds to non-ablated tissue. In some embodiments, the module applies a pixel grayscale ranging from full black to full white to create a 2D map of the depth of the lesion site along the row, wherein 0 is full black and the deepest point and 255 is full white and the shallowest point assuming 256 (0 to 255) grayscale levels, wherein the 2D map of the depth of the ablated tissue is an absolute measurement, wherein the fNADH signal intensity is normalized to a previously established fNADH / depth grayscale value. In some embodiments, a 2D map of the depth of ablated tissue is repeated multiple times along a vertical line spanning the width of the lesion site, each 2D map of the depth is parallel to a line along the length of the lesion, and each of the 2D maps of the depth of ablated tissue on the vertical line is integrated to reconstruct a 3D image of the depth of the ablated tissue. In some embodiments, irradiation, imaging, and generation are performed while tissue is ablated using radiofrequency, cryoablation, or a laser catheter. In some embodiments, irradiation and imaging are performed using a fiber optic waveguide coupled to the tip of an intraluminal catheter, which transmits ultraviolet light from an ultraviolet light source to the irradiated tissue. In some embodiments, ablation is performed using one of a radiofrequency catheter, a cryoablation catheter, or a laser ablation catheter.
[0120] In some embodiments, the system includes: a catheter having a distal end and a proximal end for imaging ablated pulmonary vein and left atrial cardiac tissue and non-ablated gaps, the catheter including an inflatable compliant or non-compliant balloon filled with a transparent fluid for displacing surrounding blood to allow visualization of NADH fluorescence at the distal end; an ultraviolet irradiation device for irradiating tissue at the distal end; and a microfiberscope for detecting the irradiated tissue at the distal end; a fluorescence camera at the proximal end coupled to the microfiberscope for creating a 2D image, the fluorescence camera including a fluorescent camera configured to capture ultraviolet radiation from the irradiated tissue a filter through which tissue passes; wherein the detected 2D image shows lesions having a dark appearance due to lack of fluorescence, gaps having a bright appearance due to normal fluorescence, and any ischemic tissue having a brighter halo-type appearance around the lesions; an ablation device for ablating cardiac tissue at a distal end based on the detected 2D image; and a module for determining the depth of the lesion along the row by plotting the detected fluorescence intensity along the row spanning the length of the lesion; wherein the lowest fluorescence intensity measurement corresponds to the deepest point of the lesion, and the highest fluorescence corresponds to non-ablated tissue. In some embodiments, the module applies a pixel grayscale ranging from full black to full white to create a 2D map of the depth of the lesion along the row, wherein 0 is full black and the deepest point, and 255 is full white and the shallowest point, assuming 256 (0 to 255) grayscale levels. Wherein, the 2D map of the depth of the ablated tissue is an absolute measurement, wherein the fNADH signal intensity is normalized to a previously established fNADH / depth grayscale value. In some embodiments, a 2D map of the depth of the ablated tissue is repeated multiple times along a vertical line spanning the width of the lesion site, each 2D map of the depth is parallel to a line along the length of the lesion, and each of the 2D maps of the depth of the ablated tissue on the vertical line is integrated to reconstruct a 3D image of the depth of the ablated tissue. In some embodiments, a display coupled to an external camera shows the detected 2D image. In some embodiments, the ablation device is an ablation catheter having a proximal end and a distal end. In some embodiments, the ablation catheter is a laser delivery catheter, a radiofrequency delivery catheter, or a cryoablation catheter.
[0121] In some embodiments, a catheter having a proximal end and a distal end for imaging ablated epicardial cardiac muscle tissue and non-ablated gaps comprises: an ultraviolet irradiation device for stimulating mitochondrial NADH of the epicardial cardiac muscle tissue; a fiberscope, which detects NADH fluorescence from the irradiated epicardial cardiac tissue at the distal end; a fluorescence camera located at the proximal end coupled to the fiberscope, for creating an image from the detected NADH fluorescence, the fluorescence camera comprising a 460nm bandpass filter to detect the NADH fluorescence captured by the microfiberscope; wherein the detected 2D image shows lesions having a dark appearance due to lack of fluorescence, gaps having a bright appearance due to normal fluorescence, and any ischemic tissue surrounding the lesions having a brighter halo-like appearance, a module for determining the depth of the lesion along a line by plotting the detected and measured fluorescence intensity along the line spanning the length of the lesion; wherein the lowest fluorescence intensity measurement corresponds to the deepest point of the lesion, and the highest fluorescence corresponds to non-ablated tissue. In some embodiments, the module applies a pixel grayscale ranging from completely black to completely white to create a 2D map of the depth of the lesion site along the row, where 0 is completely black and the darkest point, and 255 is completely white and the shallowest point, assuming 256 (0 to 255) grayscale levels. Wherein, the 2D map of the depth of the ablated tissue is an absolute measurement, where the fNADH signal intensity is normalized to the previously established fNADH / depth grayscale value. In some embodiments, the 2D map of the depth of the ablated tissue is repeated on a vertical line across the width of the lesion site, which is parallel to the row along the length of the lesion, and each of the depths of the ablated tissue on the vertical line is integrated to reconstruct a 3D image of the depth of the ablated tissue.
[0122] In some embodiments, a catheter having a proximal end and a distal end for imaging ablated epicardial cardiac muscle tissue and non-ablated gaps comprises: an ultraviolet irradiation device for exciting mitochondrial NADH of the epicardial cardiac muscle tissue at the distal end; a fluorescence camera located at the distal end for creating an image from the detected NADH fluorescence, the fluorescence camera comprising a 460nm bandpass filter to detect NADH fluorescence from the irradiated epicardial cardiac muscle tissue; wherein the detected fluorescence data shows the physiology of a lesion site having a dark appearance due to lack of fluorescence, the physiology of a gap having a bright appearance due to normal fluorescence, and the physiology of any ischemic tissue having a brighter halo-type appearance around the lesion site; and a module for determining the depth of the lesion site along a line by plotting the detected and measured fluorescence intensity along the line spanning the length of the lesion site; wherein the lowest fluorescence intensity measurement corresponds to the deepest point of the lesion site, and the highest fluorescence corresponds to non-ablated tissue. In some embodiments, the module applies a pixel grayscale ranging from completely black to completely white to create a 2D map of the depth of the lesion site along the row, where, assuming 256 (0 to 255) grayscale levels, 0 is completely black and the darkest point, and 255 is completely white and the shallowest point. Wherein, the 2D map of the depth of the ablated tissue is an absolute measurement, where the fNADH signal intensity is normalized to the previously established fNADH / depth grayscale value. In some embodiments, the 2D map of the depth of the ablated tissue is repeated on a vertical line across the width of the lesion site, which is parallel to the row along the length of the lesion, and each of the depths of the ablated tissue on the vertical line is integrated to reconstruct a 3D image of the depth of the ablated tissue.
[0123] As described above, the systems and methods of the present invention provide high-quality and verifiable lesions, which can be at least one aspect of the success of the ablation process and the avoidance of recurrence. Quality lesions can have an appropriate depth and cause cell necrosis (i.e., transmural) completely from the endocardial surface to the epicardial surface of the heart, while minimizing damage to distant non-cardiac structures. The currently disclosed systems and methods provide feedback, such as the extent of cell damage caused by ablation, and actually verify the integrity of the lesion. The currently disclosed embodiments address the lack of lesion quality feedback by providing lesion visualization and lesion depth information to the physician during the process, thereby overcoming at least some of the known technical problems. This information should prove useful in: forming and verifying appropriate lesions, reducing fluoroscopy time, and reducing the rate of arrhythmia, thereby improving results and reducing costs.
[0124] According to an embodiment of the present disclosure, systems and methods use NADH fluorescence to provide real-time direct visualization of lesions and gaps during ablation. The currently disclosed systems and methods work by detecting the fluorescence contrast between non-viable ablated myocardium and viable myocardium. The present disclosure provides lesion depth information to the physician in real time during the process.
[0125] According to some aspects of the present disclosure, the disclosed systems and methods can be used to determine the depth of lesions based on the pixel intensity obtained after ablation of tissue and imaging of the tissue using the fNADH system. An assessment of the depth of ablation lesions can be provided by correlating the image intensity provided by the fNADH system with the depth of lesions. This means that the relevant depth data can be integrated into the 3D reconstruction of the lesion, thereby giving the physician real-time feedback on the geometry and quality of the lesion.
[0126] According to some aspects of the present disclosure, a method for determining the depth of a lesion site is provided, the method comprising: irradiating cardiac tissue having a lesion site; obtaining mitochondrial nicotinamide adenine dinucleotide hydrogen (NADH) fluorescence intensity from the irradiated cardiac tissue along a first line spanning the lesion site; creating a two-dimensional (2D) map of the depth of the lesion site along the first line based on the NADH fluorescence intensity; and determining the depth of the lesion site at a selected point along the first line from the 2D map, wherein a lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and a higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0127] In some embodiments, the method further comprises forming a lesion site in the cardiac tissue by ablation. The obtaining step may comprise: detecting NADH fluorescence from the irradiated tissue; creating a digital image of the lesion site from the NADH fluorescence, the digital image comprising a plurality of pixels; and determining the NADH fluorescence intensity of a plurality of pixels along a row across the lesion site. In some embodiments, the method may further comprise distinguishing the lesion site from healthy tissue in the digital image based on the amount of NADH fluorescence from the lesion site and healthy tissue; and normalizing the digital image based on the NADH fluorescence intensity of pixels representing healthy tissue.
[0128] In some embodiments, the detecting step includes filtering the NADH fluorescence through a bandpass filter of about 435 nm to 485 nm. In some embodiments, healthy tissue has a brighter appearance, while the lesion site has a darker appearance. The creating step can include plotting the NADH fluorescence intensity along a row across the lesion site to create a 2D map of the depth of the lesion site.
[0129] In some embodiments, the method further comprises: obtaining NADH fluorescence intensity from the irradiated cardiac tissue along a second line across the lesion; creating a 2D map of the depth of the lesion along the second line based on the NADH fluorescence intensity; constructing a 3-dimensional (3D) image of the lesion from the 2D map along the first line and the 2D map along the second line. In some embodiments, the obtaining, creating, and determining steps may be repeated multiple times along a vertical line across the width of the lesion, each 2D map of the depth being parallel to the first line along the length of the lesion; and integrating each of the 2D maps of the depth of the lesion on the vertical lines to reconstruct a 3D image of the depth of the lesion.
[0130] The determining step may include applying a pixel grayscale ranging from completely black to completely white.The method may be used to analyze epicardial tissue, endocardial tissue, atrial tissue, and ventricular tissue.
[0131] In some embodiments, the irradiating step includes irradiating the cardiac tissue with UV light generated by a laser, wherein the UV light generated by the laser can have a wavelength of about 300 nm to about 400 nm.
[0132] According to some aspects of the present disclosure, a system for imaging cardiac tissue is provided, the system comprising: an irradiation device configured to irradiate tissue having a lesion site to excite nicotinamide adenine dinucleotide hydrogen (NADH) of mitochondria in the tissue; an imaging device configured to detect NADH fluorescence from the irradiated tissue; and a controller in communication with the imaging device, the controller being compiled to obtain NADH fluorescence intensity from the irradiated tissue along a first line spanning the lesion site; create a 2-dimensional (2D) map of the depth of the lesion site along the first line based on the NADH fluorescence intensity; and determine the depth of the lesion site at a selected point along the first line from the 2D map, wherein lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0133] According to some aspects of the present disclosure, a system for imaging cardiac tissue is provided, the system comprising: a catheter having a distal region and a proximal region; a light source; an optical fiber extending from the light source to the distal region of the catheter to irradiate tissue having a lesion site near the distal end of the catheter, thereby exciting nicotinamide adenine dinucleotide hydrogen (NADH) of mitochondria in the tissue; an image bundle for detecting NADH fluorescence from the irradiated tissue; a camera connected to the image bundle, the camera being configured to receive NADH fluorescence from the irradiated tissue and generate a digital image of the irradiated tissue, the digital image comprising a plurality of pixels; and a controller in communication with the camera, the controller being configured to determine, from the digital image, NADH fluorescence intensity of a plurality of pixels along a first row spanning the lesion site, create a 2D map of the depth of the lesion site along the first row based on the NADH fluorescence intensity, and determine the depth of the lesion site at a selected point along the first row based on the 2D map, wherein a lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and a higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0134] Provided are systems, catheters, and methods for treating atrial fibrillation (AF). Using a balloon-guided catheter equipped with a UV irradiation source and an optical fiber capable of conducting UV, a camera with fluorescence capability coupled to an imaging beam, and an optical bandpass filter to detect NADH fluorescence, the fluorescence of endogenous NADH (fNADH) in cardiac tissue is imaged to identify ablation areas and non-ablated areas. fNADH imaging can be used to identify gaps between ablation areas, which can then be ablated. The grayscale display of the fNADH image is used to predict the depth of the ablated lesion, and additional lesions can be delivered at lesions of inappropriate width. Imaging can be performed during the ablation process, and no additional chemicals, such as contrast agents, tracers, or dyes, are required.
[0135] The foregoing disclosure is set forth only to illustrate various non-limiting embodiments of the present disclosure and is not intended to be limiting. Because it is possible for those skilled in the art to modify the disclosed embodiments in combination with the spirit and substance of the present disclosure, the presently disclosed embodiments should be interpreted as including everything within the scope of the appended claims and their equivalents.
[0136] The following content corresponds to the original claims in the parent application and is now incorporated herein as part of the specification:
[0137] 1. A method for determining the depth of a lesion, the method comprising:
[0138] Irradiation of cardiac tissue with lesion sites;
[0139] Obtaining mitochondrial nicotinamide adenine dinucleotide hydrogen (NADH) fluorescence intensity from irradiated heart tissue along a first row spanning the lesion site;
[0140] creating a 2-dimensional (2D) map of the depth of the lesion site along the first row based on the NADH fluorescence intensity; and
[0141] The depth of the lesion at a selected point along the first row is determined from the 2D map, wherein lower NADH fluorescence intensity corresponds to greater depth in the lesion and higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0142] 2. The method according to item 1 further comprises forming a lesion site in cardiac tissue by ablation.
[0143] 3. The method according to any one of items 1 to 2, wherein the obtaining step comprises:
[0144] Detection of NADH fluorescence from irradiated tissue;
[0145] Creating a digital image of the lesion site based on the NADH fluorescence, wherein the digital image comprises a plurality of pixels; and
[0146] The NADH fluorescence intensity of the plurality of pixels along the row spanning the lesion site is determined.
[0147] 4. The method according to item 3, further comprising:
[0148] distinguishing the lesion site from the healthy tissue in the digital image based on the amount of the NADH fluorescence from the lesion site and the healthy tissue;
[0149] The digital image is normalized based on the NADH fluorescence intensity of pixels representing the healthy tissue.
[0150] 5. A method according to any one of items 1 to 4, wherein the detecting step comprises filtering NADH fluorescence through a bandpass filter of about 435 nm to 485 nm.
[0151] 6. A method according to claim 4, wherein the healthy tissue has a lighter appearance and the lesion portion has a darker appearance.
[0152] 7. A method according to any one of items 1 to 6, wherein the creating step comprises plotting the NADH fluorescence intensity along the line across the lesion site to create a 2D map of the depth of the lesion site.
[0153] 8. The method according to any one of items 1 to 7, further comprising:
[0154] Acquiring NADH fluorescence intensity from irradiated heart tissue along a second row across the lesion site;
[0155] creating a 2D map of the depth of the lesion site along the second row based on the NADH fluorescence intensity; and
[0156] A 3-dimensional (3D) image of the lesion site is constructed from the 2D image along the first row and the 2D image along the second row.
[0157] 9. The method according to any one of items 1 to 8 further comprises: repeating the obtaining, creating and determining steps multiple times along a vertical line spanning the width of the lesion site, each 2D map of the depth being parallel to the first line along the length of the lesion site; and integrating each of the 2D maps of the depth of the lesion site on the vertical line to reconstruct a 3D image of the depth of the lesion site.
[0158] 10. A method according to any one of clauses 1 to 9, wherein the determining step comprises applying a pixel grey scale ranging from completely black to completely white.
[0159] 11. The method according to any one of items 1 to 10, wherein the cardiac tissue is selected from epicardial tissue, endocardial tissue, atrial tissue and ventricular tissue.
[0160] 12. A method according to any one of items 1 to 11, wherein the irradiation step comprises irradiating the cardiac tissue using UV light generated by a laser.
[0161] 13. The method of claim 12, wherein the UV light generated by the laser has a wavelength of about 300 nm to about 400 nm.
[0162] 14. A system for imaging cardiac tissue, comprising:
[0163] an irradiation device configured to irradiate tissue having a lesion site to stimulate nicotinamide adenine dinucleotide hydrogen (NADH) of mitochondria in the tissue;
[0164] an imaging device configured to detect NADH fluorescence from the irradiated tissue; and
[0165] A controller that communicates with the imaging device and is programmed to obtain NADH fluorescence intensity from irradiated cardiac tissue along a first line spanning the lesion site; create a two-dimensional (2D) map of the depth of the lesion site along the first line based on the NADH fluorescence intensity; and determine the depth of the lesion site at a selected point along the first line from the 2D map, wherein lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0166] 15. A system according to item 14, wherein the irradiation device is a UV laser.
[0167] 16. A system according to any one of items 14 to 15, wherein the imaging device comprises a camera and a fiberscope extending from the camera to the tissue being irradiated.
[0168] 17. A system according to any one of items 14 to 16, wherein the imaging device also includes a bandpass filter of approximately 435 nm to 485 nm disposed between the camera and the fiberscope.
[0169] 18. A system according to any one of items 14 to 17, wherein the controller is also programmed to detect the NADH fluorescence from the irradiated tissue; create a digital image of the lesion site from the NADH fluorescence, the digital image comprising a plurality of pixels; and determine the NADH fluorescence intensity of the plurality of pixels along the row across the lesion site.
[0170] 19. A system according to any one of items 14 to 18, wherein the controller is also programmed to obtain NADH fluorescence intensity from irradiated cardiac tissue along a second line across the lesion site; create a 2D map of the depth of the lesion site along the second line based on the NADH fluorescence intensity; and construct a 3-dimensional (3D) image of the lesion site from the 2D map along the first line and the 2D map along the second line.
[0171] 20. A system according to any one of items 14 to 19, wherein the controller is further programmed to repeat the process multiple times along a vertical line spanning the width of the lesion site, each 2D map of the depth being parallel to the first line along the length of the lesion site; and to integrate each of the 2D maps of the depth of the lesion site on the vertical line to reconstruct a 3D image of the depth of the lesion site.
[0172] 21. A system for imaging tissue, comprising:
[0173] a catheter having a distal region and a proximal region;
[0174] light source;
[0175] an optical fiber extending from the light source to the distal region of the catheter to irradiate tissue having a lesion site near the distal end of the catheter, thereby stimulating nicotinamide adenine dinucleotide hydrogen (NADH) of mitochondria in the tissue;
[0176] an imaging beam for detecting NADH fluorescence from the irradiated tissue;
[0177] a camera connected to the imaging bundle, the camera being configured to receive the NADH fluorescence from the irradiated tissue and generate a digital image of the irradiated tissue, the digital image comprising a plurality of pixels; and
[0178] a controller in communication with the camera, the controller being configured to determine from the digital image NADH fluorescence intensity of the plurality of pixels along a first row spanning the lesion site; create a 2D map of the depth of the lesion site along the first row based on the NADH fluorescence intensity; and determine from the 2D map the depth of the lesion site at a selected point along the first row, wherein lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and higher NADH fluorescence intensity corresponds to non-ablated tissue.
[0179] 22. A system according to item 21, wherein the controller is also programmed to obtain NADH fluorescence intensity from irradiated cardiac tissue along a second line across the lesion site; create a 2D map of the depth of the lesion site along the second line based on the NADH fluorescence intensity; and construct a 3-dimensional (3D) image of the lesion site from the 2D map along the first line and the 2D map along the second line.
[0180] 23. A system according to item 21 or 22, wherein the controller is further programmed to repeat the process multiple times along a vertical line spanning the width of the lesion site, each 2D map of the depth is parallel to the first line along the length of the lesion site; and integrate each of the 2D maps of the depth of the lesion site on the vertical line to reconstruct a 3D image of the depth of the lesion site.
Claims
1. A system for imaging tissue, comprising: An irradiation device including a light source, the irradiation device being configured to irradiate a tissue having a lesion site including one or more lesions to stimulate nicotinamide adenine dinucleotide hydrogen, i.e., NADH, of mitochondria in the tissue; An imaging device comprising a sensor configured to detect NADH fluorescence from irradiated tissue ; and a controller in communication with the imaging device, the controller being programmed to receive data from the imaging device, the data indicating NADH fluorescence intensity from irradiated tissue having the lesion site; creating a digital image of the lesion site from the detected intensities of NADH fluorescence intensity at the lesion site, the digital image comprising information about the depths of the one or more lesions; analyzing the digital image of the detected NADH fluorescence intensity at the lesion site to extract information about the depths of the one or more lesions at the lesion site by creating a plurality of 2D maps of the depths of the one or more lesions at the lesion site based on the detected NADH fluorescence intensity along a plurality of lines across the digital image of the lesion site; constructing a 3D image of the lesion site from the plurality of 2D images such that the 3D image represents the depth of the one or more lesions of the lesion site; and causing the 3D image of the depth and shape of the one or more lesions to be displayed to a user.
2. The system of claim 1, wherein the irradiation device is a UV laser.
3. The system of any one of claims 1 to 2, wherein the imaging device comprises a camera and a fiberscope extending from the camera to the tissue being irradiated.
4. The system of claim 3, wherein the imaging device detects the NADH fluorescence, further comprising a 435 nm to 485 nm bandpass filter disposed between the camera and the fiberscope.
5. The system of any one of claims 1 to 2, wherein the controller is further programmed to receive the detected NADH fluorescence of the irradiated tissue from the imaging device; create a digital image of the lesion site from the NADH fluorescence, the digital image comprising a plurality of pixels; and determine the NADH fluorescence intensity of the plurality of pixels along the plurality of rows across the lesion site.
6. The system according to any one of claims 1 to 2, wherein the controller is further programmed to repeatedly create a 2D map of depth along at least one vertical line across the width of the lesion site, each of the 2D maps of depth being parallel to each other along the length of the lesion site; and to integrate each of the 2D maps of depth of the lesion site on the vertical line to reconstruct a 3D image of the depth of the lesion site.
7. The system of claim 1, wherein the plurality of rows are parallel.
8. A system according to any one of claims 1 to 2, further comprising a catheter having a distal end, which is configured to be located adjacent to a lesion site having one or more lesions in tissue and to deliver ablation energy to the tissue, wherein the catheter comprises one or more optical fibers so that the distal ends of the one or more optical fibers extend to the distal end of the catheter, wherein the one or more optical fibers communicate with the irradiation device and the imaging device.
9. The system of any one of claims 1 to 2, wherein the tissue is cardiac tissue.
10. The system according to any one of claims 1 to 2, further comprising a display configured to display a 3D image of the depth and shape of the lesion site to allow adjustment of the depth and shape of the lesion site of the tissue.
11. A system for imaging tissue, comprising: an irradiation device configured to irradiate a tissue having a lesion site including one or more lesions to stimulate nicotinamide adenine dinucleotide hydrogen (NADH) of mitochondria in the tissue; an imaging device configured to detect NADH fluorescence from the irradiated tissue; A controller in communication with the imaging device, the controller being programmed to receiving data from the imaging device, the data indicating NADH fluorescence intensity from irradiated tissue having the lesion site, Creating a digital image of the lesion site from the detected intensity of the NADH fluorescence intensity of the lesion site, the digital image containing information about the depth of the lesion site; Analyzing the digital image of the detected NADH fluorescence intensity of the lesion site to extract information about the depth of the one or more lesions of the lesion site by creating a plurality of 2-dimensional (2D) maps of the depth of the one or more lesions of the lesion site along a plurality of lines of the digital image across the lesion site based on the detected NADH fluorescence intensity; as well as A 3-dimensional (3D) image of the lesion site is constructed from the plurality of 2D images such that the 3D image represents the depth of the one or more lesions of the lesion site.
12. The system of claim 11, wherein the irradiation device is a UV laser.
13. The system of any one of claims 11 to 12, wherein the imaging device comprises a camera and a fiberscope extending from the camera to the tissue being irradiated.
14. A system according to any one of claims 11 to 12, wherein the controller is further programmed to receive detected NADH fluorescence from irradiated tissue from the imaging device; create a digital image of the lesion site from the NADH fluorescence, the digital image comprising a plurality of pixels; and determine the NADH fluorescence intensity of the plurality of pixels along the plurality of rows across the lesion site.
15. The system of claim 11, wherein the plurality of rows are parallel.
16. A system according to any one of claims 11 to 12, further comprising a catheter having a distal end, which is configured to be located adjacent to a lesion site having one or more lesions in tissue and to deliver ablation energy to the tissue, wherein the catheter comprises one or more optical fibers such that the distal ends of the one or more optical fibers extend to the distal end of the catheter, wherein the one or more optical fibers communicate with the irradiation device and the imaging device.
17. The system of any one of claims 11 to 12, wherein the tissue is cardiac tissue.
18. The system of any one of claims 11 to 12, further comprising a display configured to display a 3D image of the depth and shape of the lesion site to allow adjustment of the depth and shape of the lesion site of the tissue.
